I 

117TH CONGRESS 

1ST SESSION H. R. 1391 

To direct the Secretary of Health and Human Services and other Federal 

officials to compile into a searchable database information relating to 

Federal support for biomedical research and development related to 

COVID–19, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 26, 2021 

Mr. DOGGETT (for himself, Ms. BARRAGA ́N, Mrs. BEATTY, Mr. BEYER, Mr. 

BISHOP of Georgia, Mr. BLUMENAUER, Ms. CHU, Mr. CICILLINE, Mr. 

COHEN, Mr. COURTNEY, Mr. DEFAZIO, Ms. DEGETTE, Ms. DELAURO, 

Mr. DESAULNIER, Mrs. DINGELL, Mr. EVANS, Mr. GREEN of Texas, Mr. 

GRIJALVA, Mr. HASTINGS, Mrs. HAYES, Ms. JAYAPAL, Ms. JOHNSON of 

Texas, Ms. KAPTUR, Mr. KHANNA, Mr. KILDEE, Ms. LEE of California, 

Mr. LEVIN of Michigan, Mr. LOWENTHAL, Ms. MENG, Mr. NADLER, Mrs. 

NAPOLITANO, Ms. NORTON, Ms. PINGREE, Mr. POCAN, Ms. PORTER, Ms. 

SCANLON, Ms. SCHAKOWSKY, Ms. SPANBERGER, Mr. SUOZZI, Mr. 

TAKANO, Ms. TITUS, Mr. TRONE, Mr. VARGAS, Mr. WELCH, and Mr. 

TONKO) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committees on 

Armed Services, Veterans’ Affairs, Science, Space, and Technology, the 

Judiciary, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions 

as fall within the jurisdiction of the committee concerned 

A BILL 

To direct the Secretary of Health and Human Services and 

other Federal officials to compile into a searchable database information relating to Federal support for biomedical research and development related to COVID– 

19, and for other purposes. 


pamtmann on DSKBC07HB2PROD with BILLS
2 

•HR 1391 IH

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Taxpayer Research 

5 and Coronavirus Knowledge Act of 2021’’. 

6 SEC. 2. DATABASE. 

7 (a) IN GENERAL.—The Secretary of Health and 

8 Human Services, the Director of the National Institutes 

9 of Health, the Assistant Secretary for Preparedness and 

10 Response of the Department of Health and Human Serv11 ices, the Director of the Biomedical Advanced Research 

12 and Development Authority, the Secretary of Defense, the 

13 Secretary of Veterans Affairs, the Director of the National 

14 Institute of Allergy and Infectious Diseases, and such 

15 other Federal officials as the Secretary of Health and 

16 Human Services determines to be relevant, acting in co17 ordination, shall— 

18 (1) compile into a searchable database informa19 tion relating to Federal support (before or after the 

20 date of enactment of this Act) for biomedical re21 search and development related to COVID–19 (in22 cluding biomedical research and development relat23 ing to a product or therapy that was later modified 

24 or repurposed to be used for COVID–19); and 


pamtmann on DSKBC07HB2PROD with BILLS
3 

•HR 1391 IH

1 (2) make such database available on the public 

2 website of the Department of Health and Human 

3 Services. 

4 (b) COVERED INFORMATION.—The information relat5 ing to Federal support referred to in subsection (a)(1) in6 cludes all contracts, funding agreements, licensing ar7 rangements, other transactions, and other arrangements 

8 entered into by or on behalf of the Federal Government 

9 and tax benefits provided with respect to research and de10 velopment, and manufacturing, of a drug (including a bio11 logical product), cell or gene therapy, or medical device 

12 intended to be manufactured, used, designed, developed, 

13 modified, repurposed, licensed, or procured to diagnose, 

14 mitigate, prevent, treat, or cure COVID–19, including the 

15 following: 

16 (1) Licensing agreements pursuant to section 

17 207 or 209 of title 35, United States Code. 

18 (2) Cooperative research and development 

19 agreements and licensing agreements pursuant to 

20 section 3710a of title 15, United States Code. 

21 (3) Funding agreements, as defined under sec22 tion 201 of title 35, United States Code. 

23 (4) Transactions, contracts, grants, cooperative 

24 agreements, other agreements, and other arrangeVerDate Sep 11 2014 15:45 Mar 24, 2021 Jkt 019200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\H1391.IH H1391

pamtmann on DSKBC07HB2PROD with BILLS
4 

•HR 1391 IH

1 ments entered into pursuant to the following stat2 utes: 

3 (A) The Public Health Service Act (42 

4 U.S.C. 201 et seq.), including sections 301, 

5 319L, 421, and 480 of such Act (42 U.S.C. 

6 241, 247d–7e, 285b–3, 287a). 

7 (B) Section 105 of the National Institutes 

8 of Health Reform Act of 2006 (42 U.S.C. 

9 284n). 

10 (C) Chapter 139 of title 10, United States 

11 Code (10 U.S.C. 2351 et seq.), including sec12 tions 2358, 2371, 2371a, 2371b, and 2373. 

13 (5) Grants, contracts, and other transactions 

14 pursuant to section 2371, 2371a, or 2371b of title 

15 10, United States Code. 

16 (6) Procurement contracts and other agree17 ments pursuant to section 2373 of title 10, United 

18 States Code. 

19 (c) INFORMATION REQUIRED.—Notwithstanding any 

20 other provision of law, the Federal officials referred to in 

21 subsection (a) shall include in the database under sub22 section (a), with regard to each contract, funding agree23 ment, licensing agreement, other transaction, other ar24 rangement, or tax benefit described in subsection (b), at 

25 least the following information: 


pamtmann on DSKBC07HB2PROD with BILLS
5 

•HR 1391 IH

1 (1) The agency, program, institute, or other 

2 Federal Government entity providing the Federal 

3 grant, cooperative agreement, or other support. 

4 (2) The amount and period of Federal financial 

5 support with an itemized breakdown. 

6 (3) Other Federal nonfinancial support, includ7 ing the use of Federal personnel, Federal facilities, 

8 and Federal equipment. 

9 (4) The grant number, if applicable. 

10 (5) Associated clinical trial data, upon trial 

11 completion. 

12 (6) Associated patents and patent applications, 

13 specifying— 

14 (A) any Federal ownership in such patents 

15 and patent applications; 

16 (B) the expiration date of such patents 

17 and filing dates of such patent applications; and 

18 (C) the numbers of such patents and pat19 ent applications. 

20 (7) Associated periods of marketing exclusivity 

21 under Federal law and the durations of such peri22 ods. 

23 (8) The corporation, nonprofit organization, 

24 academic institution, person, or other entity receiv25 ing the Federal support. 


pamtmann on DSKBC07HB2PROD with BILLS
6 

•HR 1391 IH

1 (9) Any products (including repurposed prod2 ucts) approved, authorized, or cleared for marketing, 

3 or for which marketing approval, authorization, or 

4 clearance is being sought, the development of which 

5 was aided by Federal support, including— 

6 (A) the names of such products; 

7 (B) the prices of such products; and 

8 (C) the current and anticipated manufac9 turing capacity to produce such products. 

10 (10) The full terms of the contract, funding 

11 agreement, licensing agreement, other transaction, 

12 or other arrangement described in subsection (b). 

13 (d) FORMAT OF INFORMATION.—The database under 

14 subsection (a) shall be— 

15 (1) searchable and filterable according to the 

16 categories of information described in subsection (c); 

17 and 

18 (2) presented in a user-friendly format. 

19 (e) TIMING.—The database under subsection (a) 

20 shall be— 

21 (1) made publicly available not later than 1 

22 month of the date of enactment of this Act; and 

23 (2) updated not less than every 2 weeks. 

24 (f) DISCLOSURE.— 


pamtmann on DSKBC07HB2PROD with BILLS
7 

•HR 1391 IH

1 (1) IN GENERAL.—Notwithstanding any other 

2 provision of law, to the extent necessary for an offi3 cial referred to in subsection (a) to carry out this 

4 section, such official may require entities receiving 

5 Federal support referred to in subsection (a)(1) to 

6 disclose to the official any information relating to 

7 such Federal support and required to be included in 

8 the database under subsection (a). 

9 (2) INTERMEDIARY COOPERATION.—Any ar10 rangement entered into by the Federal Government 

11 with an entity providing for such entity to enter into 

12 contracts, licensing agreements, grants, other trans13 actions, or other arrangements with third parties on 

14 behalf of the Federal Government shall require such 

15 entity to disclose in a timely manner any informa16 tion necessary for the Federal Government to fulfill 

17 its duties under this Act. With respect to any such 

18 arrangement in place as of the date of enactment of 

19 this Act, an official referred to in subsection (a) may 

20 require the entity to disclose to the official any infor21 mation required to be included in the database 

22 under subsection (a). 

23 (3) PENALTY FOR NONDISCLOSURE.—If an en24 tity that is required to disclose information pursuant 

25 to paragraph (1) or (2) fails to disclose such inforVerDate Sep 11 2014 15:45 Mar 24, 2021 Jkt 019200 PO 00000 Frm 00007 Fmt 6652 Sfmt 6201 E:\BILLS\H1391.IH H1391

pamtmann on DSKBC07HB2PROD with BILLS
8 

•HR 1391 IH

1 mation by the date that is two weeks after the date 

2 on which the official requests such information, or 

3 by such reasonable deadline as the official may 

4 specify, whichever is sooner, then such entity shall 

5 be liable to the United States for a civil penalty in 

6 an amount not to exceed $10,000 for each day on 

7 which such failure continues. 

Æ 


pamtmann on DSKBC07HB2PROD with BILLS